Home  /  Resource Library  /  A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination As Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma

A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination As Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma

ASH 2020: Retrospective study examined the combination of brentuximab vedotin combined with pembrolizumab for treatment of relapsed Hodgkin lymphoma.